secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adagio Medical Holdings, Inc. (ADGM)
CIK:        0002006986
Form:       8-K
Filed at:   2024-11-01T23:59:59+00:00
Accession:  0001558370-24-014144
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Adagio Medical announces restatement of FY2023, Q1 and Q2 2024 financials; material weakness identified
--------------------------------------------------------------------------------

- Audit committee concluded FY2023 audited and Q1/Q2 2024 unaudited statements should not be relied upon due to accrued interest misstatement.
- Error found during Q3 2024 prep; overstatement of accrued interest on convertible notes and other liabilities.
- Company will restate financials via Amendment No. 2 to the Business Combination Super 8-K.
- Material weakness in internal control over financial reporting regarding review of third-party valuation reports for debt/equity.
- Remediation plan includes additional review of valuation reports, manual journal entries, and enhanced oversight controls.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2006986/000155837024014144/0001558370-24-014144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2006986/000155837024014144/adgm-20241101x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer